Novavax Inc. (NASDAQ: NVAX) is 2888.94% higher on its value in year-to-date trading and has touched a low of $3.65 and a high of $189.40 in the current 52-week trading range. The NVAX stock was last observed hovering at around $120.27 in the last trading session, with the day’s loss setting it -1.31% off its average median price target of $209.00 for the next 12 months. It is also 46.65% off the consensus price target high of $223.00 offered by 7 analysts, but current levels are -58.61% lower than the price target low of $75.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $118.96, the stock is -3.67% and 13.17% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.79 million and changing -1.09% at the moment leaves the stock 40.71% off its SMA200. NVAX registered 2888.94% gain for a year compared to 6-month gain of 49.26%. The firm has a 50-day simple moving average (SMA 50) of $112.48 and a 200-day simple moving average (SMA200) of $110.09.
The stock witnessed a -14.72% loss in the last 1 month and extending the period to 3 months gives it a 9.79%, and is 3.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.21% over the week and 9.78% over the month.
Novavax Inc. (NVAX) has around 165 employees, a market worth around $7.47B and $204.80M in sales. Fwd P/E is 6.74. Distance from 52-week low is 3157.57% and -37.19% from its 52-week high.
Novavax Inc. (NVAX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Novavax Inc. (NVAX) is a “Overweight”. 7 analysts offering their recommendations for the stock have an average rating of 2.40, where 1 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Novavax Inc. is expected to release its quarterly report on 03/01/2021 and quarterly earnings per share for the current quarter are estimated at -$1.31 with sales reaching $347.92M over the same period.The EPS is expected to grow by 44.90% this year, but quarterly earnings will post 2,814.30% year-over-year. Quarterly sales are estimated to grow 3,846.50% in year-over-year returns.
Novavax Inc. (NVAX) Top Institutional Holders
401 institutions hold shares in Novavax Inc. (NVAX), with 274.58k shares held by insiders accounting for 0.43% while institutional investors hold 50.76% of the company’s shares. The shares outstanding are 63.66M, and float is at 62.93M with Short Float at 11.49%. Institutions hold 50.54% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 5.43 million shares valued at $588.51 million. The investor’s holdings represent 8.53% of the NVAX Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 4.3 million shares valued at $465.55 million to account for 6.75% of the shares outstanding. The other top investors are Franklin Resources, Inc. which holds 2.25 million shares representing 3.53% and valued at over $243.54 million, while State Street Corporation holds 2.68% of the shares totaling 1.71 million with a market value of $185.15 million.
Novavax Inc. (NVAX) Insider Activity
The most recent transaction is an insider sale by Erck Stanley C, the company’s President and CEO. SEC filings show that Erck Stanley C sold 52,316 shares of the company’s common stock on Nov 16 at a price of $90.65 per share for a total of $4.74 million. Following the sale, the insider now owns 20495.0 shares.
Novavax Inc. disclosed in a document filed with the SEC on Oct 01 that Erck Stanley C (President and CEO) sold a total of 2 shares of the company’s common stock. The trade occurred on Oct 01 and was made at $108.57 per share for $217.0. Following the transaction, the insider now directly holds 20494.0 shares of the NVAX stock.
Still, SEC filings show that on Sep 30, Trizzino John (EVP, CBO and CFO) disposed off 2,250 shares at an average price of $110.22 for $0.25 million. The insider now directly holds 5,087 shares of Novavax Inc. (NVAX).